EichorEICHOR
Condition: Lymphoplasmacytoid Lymphoma Synced from ClinicalTrials.gov · August 09, 2026

Recruiting studies: Lymphoplasmacytoid Lymphoma

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

A Study of Pirtobrutinib, Venetoclax, and Rituximab in People With Waldenström's Macroglobulinemia (WM)/Lymphoplasmacyti
Phase 2 · 9 location(s) · Memorial Sloan Kettering Cancer Center · NCT07231952Q702 for the Treatment of Patients With Hematologic Malignancies
Phase 1 · 2 location(s) · Mayo Clinic · NCT06712810Study of SGR-1505 in Mature B-Cell Neoplasms
Phase 1 · 36 location(s) · Schrödinger, Inc. · NCT05544019Dose Escalation and Dose Expansion Study of MDX2003 in Patients With Different Types of Lymphoma
Phase 1/Phase 2 · 2 location(s) · ModeX Therapeutics, An OPKO Health Company · NCT07249905Natural History Study of Monoclonal B Cell Lymphocytosis (MBL), Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Phase N/A · 1 location(s) · National Heart, Lung, and Blood Institute (NHLBI) · NCT00923507Combating Cancer-Related Fatigue: A Personalized Supportive Care Program
NA · 1 location(s) · UNC Lineberger Comprehensive Cancer Center · NCT06860880AutologousCD22 Chimeric Antigen Receptor (CAR)T Cells in w/Recurrent/Refractory B Cell Lymphomas
Phase 1 · 1 location(s) · Stanford University · NCT06340737Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological M
Phase 2 · 1 location(s) · Fred Hutchinson Cancer Center · NCT04195633Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders
Phase 2 · 1 location(s) · Masonic Cancer Center, University of Minnesota · NCT03314974A Study of Lonitoclax (ZE50-0134) in Relapsed or Refractory B-cell Malignancies
Phase 1 · 5 location(s) · Lomond Therapeutics Holdings, Inc. · NCT06708897Local Manufacture of CAR T-Cell Products for the Treatment of B-Cell Lymphoma and B-Acute Lymphoblastic Leukemia
Phase 2 · 1 location(s) · John Lister · NCT05281809Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib Plus Rituximab or Z
Phase 2 · 138 location(s) · National Cancer Institute (NCI) · NCT04840602Acalabrutinib and Obinutuzumab for the Treatment of Previously Untreated Follicular Lymphoma or Other Indolent Non-Hodgk
Phase 2 · 1 location(s) · Emory University · NCT04883437A Phase 2 Study to Evaluate the Safety and Efficacy of Pacritinib in Relapsed or Refractory Waldenström Macroglobulinemi
Phase 2 · 1 location(s) · Shayna Sarosiek, MD · NCT06986174Anti-CD19 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma
Phase 1 · 1 location(s) · C. Babis Andreadis · NCT0454576264Cu-LLP2A for Imaging Hematologic Malignancies
EARLY_Phase 1 · 1 location(s) · Washington University School of Medicine · NCT06636175
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →
Eichor
Clinical intelligence from public evidence
Use of Eichor is governed by our Terms of Use · Privacy Policy
© 2026 Biomedistats LLC (dba Eichor)

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.